Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now

Page 7 of 12

6. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 85

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.

On April 29, AbbVie Inc. (NYSE:ABBV) announced the FDA approval of Rinvoq for treating adults with giant cell arteritis. The approval followed the European Commission’s recent marketing authorization of Rinvoq to treat GCA in adult patients.

The same day, Guggenheim analyst Vamil Divan raised the firm’s price target on AbbVie Inc. (NYSE:ABBV) to $216 from $214, keeping a Buy rating on the shares. The analyst noted that the company reported an “an impressive quarter,” with fiscal Q1 2025 results exceeding expectations in both quarterly EPS and sales. This led to the analyst updating the firm’s model on AbbVie Inc. (NYSE:ABBV).

The company’s net revenue for fiscal Q1 2025 came to $13.343 billion, undergoing an 8.4% growth on a reported basis or 9.8% on operational basis. Adjusted diluted EPS reached $2.46, reflecting a 6.5% increase.

Page 7 of 12